艾瓦布拉丁在急性心肌梗塞中:随机对照试验的系统审查和元分析
相关实验视频
Updated: Jan 18, 2026

06:13
The Intra-Aortic Balloon Pump
Published on: February 5, 2021
24.3K
Chia Siang Kow1,2, Abdullah Faiz Zaihan3, Syed Shahzad Hasan2
1School of Pharmacy, Faculty of Medical and Life Sciences, Sunway University, Petaling Jaya, Malaysia.
Expert review of cardiovascular therapy
|January 15, 2026
概括
伊瓦布拉丁可以减少急性心肌梗塞 (AMI) 患者的主要不良心血管事件 (MACE) 和心力衰竭. 虽然它没有显著降低全因死亡率,但它作为辅助疗法具有前景.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 伊瓦布拉丁用于稳定性心痛和慢性心力衰竭.
- 它在急性心肌梗塞 (AMI) 中的疗效需要进一步研究.
研究的目的:
- 评估伊瓦布拉丁对AMI患者死亡率,MACE和心力衰竭的影响.
- 评估伊瓦布拉丁在AMI后的标准护理中的作用.
主要方法:
- 15项随机对照试验 (RCT) 的系统审查和元分析,涉及2220名患者.
- 主要结局:全因死亡率,MACE,心力衰竭发病率.
- 随机效应模型与灵敏度和偏差分析.
主要成果:
- 伊瓦布拉丁并没有显著降低所有原因的死亡率 (OR 0.66).
- 显著减少MACE (OR 0.49) 和心力衰竭事件 (OR 0.60).
- 当与β-阻断剂结合使用时观察到更大的益处;灵敏度分析证实了这些发现.
结论:
- 伊瓦布拉丁可以减少心血管并发症,特别是MACE和心力衰竭,在AMI之后.
- 它显示出作为标准AMI治疗的有价值补充的潜力.
- 建议进行进一步的大规模临床试验.
相关概念视频
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1.6K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.6K
Acute Coronary Syndrome III: Diagnostic Studies
218
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
218
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K
Antianginal Drugs: Nitrates and β-Blockers
1.4K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.4K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.8K

